AWM Investment Company’s Akari Therapeutics AKTX Stock Holding History

AWM Investment Company’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-855	Closed	-$2.96M	–	92
2017 Q4	$2.96M	Buy	+855	New	+$3.3M	0.57%	53

Other funds holding AKTX

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AWM Investment Company's AKTX Position: Q1 2018 in Review

AWM Investment Company sold out of Akari Therapeutics (AKTX) in Q1 2018, closing a stake of 855 shares — an estimated $2.96M sold.

AWM Investment Company first reported a position in AKTX in Q4 2017 and held it in 1 quarter. The position peaked at $2.96M in Q4 2017. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2018.

AWM Investment Company reported no remaining Akari Therapeutics position as of Q1 2018 after selling out during the quarter.
AWM Investment Company sold 855 Akari Therapeutics shares in Q1 2018, an estimated $2.96M.
AWM Investment Company first reported a position in Akari Therapeutics in Q4 2017 and held it in 1 quarter.
AWM Investment Company's Akari Therapeutics position peaked at $2.96M in Q4 2017.
9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2018.

Based on AWM Investment Company's 13F filing for Q1 2018, filed 10 May 2018.